Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib Monotherapy in HRRm or HRD Positive Advanced Cancer
NCT03742895Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 2 trial of olaparib in solid tumor, sponsored by Merck & Co.. Started Dec 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03742895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03742895.